Search
Search Results
-
Deficiency of leucine-rich repeat kinase 2 aggravates thioacetamide-induced acute liver failure and hepatic encephalopathy in mice
BackgroundHepatic encephalopathy (HE) is closely associated with inflammatory responses. However, as a crucial regulator of the immune and...
-
Loss of pleckstrin homology domain and leucine-rich repeat protein phosphatase 2 has protective effects on high glucose-injured retinal ganglion cells via the effect on the Akt–GSK–3β–Nrf2 pathway
ObjectivePleckstrin homology domain and leucine-rich repeat protein phosphatase 2 (PHLPP2) is linked to various pathological states. However, whether...
-
Small Leucine-Rich Proteoglycans Regulate Cancer Cell Growth, Apoptosis, and Associated Inflammation
The tumor microenvironment, apart from tumor cells, contains tissue nonmalignant cells, blood vessels, stromal cells, infiltrating immune cells, and...
-
Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan
Variants of leucine-rich repeat kinase 2 ( LRRK2 ) are the most common genetic cause of familial Parkinson’s disease (PD). We aimed to investigate the...
-
RedOx regulation of LRRK2 kinase activity by active site cysteines
Mutations of the human leucine-rich repeat kinase 2 (LRRK2) have been associated with both, idiopathic and familial Parkinson’s disease (PD). Most of...
-
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression
BackgroundMutations in leucine-rich repeat kinase 2 ( LRRK2 ) are the most common cause of familial Parkinson’s disease (PD). These mutations elevate...
-
Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine physiology in VPS35 p.D620N knock-in mice
Dysregulation of dopamine neurotransmission profoundly affects motor, motivation and learning behaviors, and can be observed during the prodromal...
-
A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells
Parkinson´s disease (PD) is a common neurodegenerative movement disorder and leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target...
-
Small Leucine-Rich Proteoglycans (SLRPs) and Biomineralization
Small leucine-rich proteoglycans (SLRPs) represent the largest family of proteoglycans consisting of 18–19 members. They play diverse structural and...
-
Parkinson’s disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging
BackgroundMultiple missense mutations in Leucine-rich repeat kinase 2 (LRRK2) are associated with familial forms of late onset Parkinson’s disease...
-
Lineage-specific protein repeat expansions and contractions reveal malleable regions of immune genes
Functional diversification, a higher evolutionary rate, and intense positive selection help a limited number of immune genes interact with many...
-
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease
Leucine-rich repeat kinase 2 (LRRK2) is a kinase involved in different cellular functions, including autophagy, endolysosomal pathways, and immune...
-
Identification of PP2A and S6 Kinase as Modifiers of Leucine-Rich Repeat Kinase-Induced Neurotoxicity
Mutations in LRRK2 are currently recognized as the most common monogenetic cause of Parkinsonism. The elevation of kinase activity of LRRK2 that...
-
G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
Pathogenic mutations in LRRK2 cause Parkinson’s disease (PD). The G2019S variant is the most common, which results in abnormally high kinase...
-
Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype
BackgroundLeucine-rich repeat kinase 2 (LRRK2) is a common gene implicated in Parkinson’s disease (PD) and is also thought to be fundamentally...
-
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
The RAS/mitogen-activated protein kinase (MAPK) signaling cascade is commonly dysregulated in human malignancies by processes driven by RAS or RAF ...
-
The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology
In Parkinson’s disease (PD) misfolded alpha-synuclein (aSyn) accumulates in the substantia nigra, where dopaminergic neurons are progressively lost....
-
Circular RNAs: Regulators of endothelial cell dysfunction in atherosclerosis
Endothelial cell (EC) dysfunction is associated with atherosclerosis. Circular RNAs (circRNAs) are covalently closed loops formed by back-splicing,...
-
LRRK2 Kinase Inhibitor PF-06447475 Protects Drosophila melanogaster against Paraquat-Induced Locomotor Impairment, Life Span Reduction, and Oxidative Stress
Parkinson’s disease (PD) is a complex multifactorial progressive neurodegenerative disease characterized by locomotor alteration due to the specific...
-
Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease
Missense variants in leucine-rich repeat kinase 2 (LRRK2) lead to familial and sporadic Parkinson’s disease (PD). The pathological features of PD...
